Medtronic Transvene has 5.2% fracture rate in Oregon study.
This article was originally published in The Gray Sheet
Executive SummaryMEDTRONIC TRANSVENE LEAD 5.2% FRACTURE RATE DATA "reaffirm" the need for "routine surveillance" of implantable defibrillator lead system complications, Blair Halperin, MD, Oregon Health Sciences University, Portland, Oregon, said Nov. 13 at the American Heart Association scientific sessions in Anaheim, California.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.